Q-linea AB (OSTO:QLINEA)
kr 2.75 -0.03 (-1.08%) Market Cap: 321.30 Mil Enterprise Value: 357.43 Mil PE Ratio: 0 PB Ratio: 4.72 GF Score: 58/100

Q3 2020 Q Linea AB Earnings Call Transcript

Nov 05, 2020 / 12:00PM GMT
Release Date Price: kr147 (-0.68%)
Jonas Jarvius
Q Linea AB - CEO

First of all, welcome to our presentation today. We are going to announce our achievements and financial position during the third quarter. Before, we read into the presentation, I would like to call up the next slide, which shows our disclaimer in case any around that if we make any forward-looking statements. But with us, I would present the next slide. We just really in the third quarter at about a high level. And of course, we'll provide more details during the rest of the presentation. As you know, clearly, we are developing innovative and disruptive solutions for faster and better infectious disease diagnostics. The first products historically is Sepsis. But ASTar is really built as a platform to support many other applications to follow blood cultures.

If I'm going to highlight one thing in particular during the third quarter, I would say that it's really the excellent feedback we received for clinical use of ASTard at Uppsala University Hospital. I will come back to that. But it really indicates that all work we have performed during the last couple of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot